JP2024506647A5 - - Google Patents
Info
- Publication number
- JP2024506647A5 JP2024506647A5 JP2023548583A JP2023548583A JP2024506647A5 JP 2024506647 A5 JP2024506647 A5 JP 2024506647A5 JP 2023548583 A JP2023548583 A JP 2023548583A JP 2023548583 A JP2023548583 A JP 2023548583A JP 2024506647 A5 JP2024506647 A5 JP 2024506647A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- transmembrane domain
- seq
- ccr4
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148489P | 2021-02-11 | 2021-02-11 | |
| US63/148,489 | 2021-02-11 | ||
| PCT/US2022/015981 WO2022173950A1 (en) | 2021-02-11 | 2022-02-10 | Ccr4-targeting chimeric antigen receptor cell therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506647A JP2024506647A (ja) | 2024-02-14 |
| JP2024506647A5 true JP2024506647A5 (https=) | 2025-02-19 |
Family
ID=82837290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548583A Pending JP2024506647A (ja) | 2021-02-11 | 2022-02-10 | Ｃｃｒ４ターゲティングキメラ抗原受容体細胞療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240122981A1 (https=) |
| EP (1) | EP4291207A4 (https=) |
| JP (1) | JP2024506647A (https=) |
| KR (1) | KR20230171919A (https=) |
| CN (1) | CN117500838A (https=) |
| AU (1) | AU2022220694A1 (https=) |
| CA (1) | CA3207861A1 (https=) |
| WO (1) | WO2022173950A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070172476A1 (en) * | 2005-07-28 | 2007-07-26 | Kyowa Hakko Kogyo Co., Ltd. | Method of treating B-cell neoplasms or Hodgkin's lymphoma |
| CA2773579C (en) * | 2009-09-10 | 2019-01-15 | Kyowa Kirin Co., Ltd. | Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4) |
| CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| EP3233900A2 (en) * | 2014-12-19 | 2017-10-25 | Dana-Farber Cancer Institute, Inc. | Chimeric antigen receptors and methods of use thereof |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| WO2018057585A1 (en) * | 2016-09-21 | 2018-03-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use |
| TW201825119A (zh) * | 2016-11-30 | 2018-07-16 | 日商協和醱酵麒麟有限公司 | 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法 |
| CN113454117B (zh) * | 2018-12-19 | 2025-07-04 | 宾夕法尼亚大学董事会 | Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途 |
| CN113924103B (zh) * | 2019-03-06 | 2025-02-14 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
| US20220145325A1 (en) * | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CN114051532A (zh) * | 2019-05-24 | 2022-02-15 | 希望之城公司 | 用于治疗ccr4阳性恶性肿瘤的经ccr4靶向性嵌合抗原受体修饰的t细胞 |
| CA3136281C (en) * | 2019-05-30 | 2024-06-25 | Shandong Boan Biotechnology Co., Ltd. | Antibody or chimeric antigen receptor which targets claudin 18.2 |
-
2022
- 2022-02-10 KR KR1020237030757A patent/KR20230171919A/ko active Pending
- 2022-02-10 EP EP22753341.1A patent/EP4291207A4/en active Pending
- 2022-02-10 WO PCT/US2022/015981 patent/WO2022173950A1/en not_active Ceased
- 2022-02-10 AU AU2022220694A patent/AU2022220694A1/en active Pending
- 2022-02-10 JP JP2023548583A patent/JP2024506647A/ja active Pending
- 2022-02-10 CN CN202280027359.0A patent/CN117500838A/zh active Pending
- 2022-02-10 US US18/276,582 patent/US20240122981A1/en active Pending
- 2022-02-10 CA CA3207861A patent/CA3207861A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548778A5 (https=) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2016514462A5 (https=) | ||
| JP2022512882A5 (https=) | ||
| US20210128618A1 (en) | Bcma-targeted car-t cell therapy of multiple myeloma | |
| KR20210049806A (ko) | Nef-함유 T 세포 및 이의 생산 방법 | |
| AU2021338819A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
| JP2021520780A (ja) | Ｎｋｇ２ｄキメラ抗原受容体 | |
| CA3199897A1 (en) | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity | |
| CA3110858A1 (en) | Methods and compositions comprising b7h3 chimeric antigen receptors | |
| CN114828862A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| RS65802B1 (sr) | Kompozicije i postupci za lečenje egfr pozitivnih kancera | |
| IL304857A (en) | Preparations and methods for treating HER2 POSITIVE cancer | |
| CN112204135B (zh) | 一种表达cd3抗体受体复合物的免疫细胞及其用途 | |
| EP4598567A2 (en) | Novel anti-mesothelin chimeric antigen receptors and modified immune cells | |
| JP2022526720A5 (https=) | ||
| IL303060A (en) | Chimeric receptors and methods of their use | |
| JP2024506647A5 (https=) | ||
| US20220370498A1 (en) | Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla gene | |
| US20220315931A1 (en) | Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin gene | |
| WO2021004400A1 (zh) | 一种表达cd3抗体受体复合物的免疫细胞及其用途 | |
| CN120712289A (zh) | 抗原结合结构域及其使用方法 | |
| RU2843842C1 (ru) | Композиции и способы для лечения egfr-положительных форм рака | |
| US20250262300A1 (en) | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy | |
| TWI915404B (zh) | 用於治療ｅｇｆｒ陽性癌症之組合物及方法 |